Table 3.
Clinical trials with CSF1/CSF1R inhibitors in combination with cancer immunotherapy agents
| Class | Target | Compound/Class | Combination partner | Clinical phase | Sponsor | Indication | ClinicalTrials.gov identifier | Status/Results | Reference |
|---|---|---|---|---|---|---|---|---|---|
| Small molecule | CSF1R (and cKIT, Flt3) | Pexidartinib (PLX3397, PLX108-01) | Pembrolizumab (anti-PD1 mAb) | 1/2 | Plexxikon/Daiichi Sankyo | Solid tumors, malignant melanoma GIST, NSCLC, ovarian carcinoma, TNBC, SCCHN, UBC, pancreatic cancer, gastric carcinoma, leiomyosarcoma, cholangio carcinoma, CRC (MSS) |
NCT02452424 | Ongoing | [74] |
| Durvalumab (anti-PDL1 mAb) | 1 | Astra Zeneca | Pancreatic carcinoma, CRC | NCT02777710 | Ongoing | - | |||
| CSF1R | ARRY-382 | Pembrolizumab (anti-PD1 mAb) | 1 | Array BioPharma | Solid tumors, melanoma, NSCLC | NCT02880371 | Ongoing | - | |
| CSF1R | BLZ945 | PDR001 (anti-PD1 mAb) | 1/2 | Novartis | Solid tumors | NCT02829723 | Ongoing | - | |
| Monoclonal antibody | CSF1R | Emactuzumab (RG7155) | Atezolizumab (anti-PDL1 mAb) | 1 | Roche | Solid tumors, TNBC, gastric cancer, soft tissue sarcoma, UBC, ovarian cancer, NSCLC, melanoma | NCT02323191 | Ongoing | - |
| RG7876 (CD40 agonist mAb) | 1 | Roche | TNBC, gastric cancer, mesothelioma, CRC, melanoma, pancreatic cancer | NCT02760797 | Ongoing | - | |||
| CSF1R | AMG820 | Pembrolizumab (anti-PD1 mAb) | 1 | Amgen | Solid tumors | NCT02713529 | Ongoing | - | |
| CSF1R | Cabiralizumab (FPA008) | Nivolumab (anti-PD1 mAb) | 1 | FivePrime/BMS | Solid tumors, NSCLC, SCCHN, pancreatic cancer, ovarian cancer, RCC, GBM | NCT02526017 | Ongoing | [75] | |
| CSF1R | IMC-CS4 (LY3022855) | Durvalumab (anti-PDL1 mAb) or Tremelimumab (anti-CTLA4 mAb) | 1 | Eli Lilly | Solid tumors | NCT02718911 | Ongoing | [76] | |
| CSF1 | MCS110 | PDR001 (anti-PD1 mAb) | 1/2 | Novartis | Solid tumors, TNBC, pancreatic cancer, melanoma, endometrial cancer | NCT02807844 | Ongoing | - | |
| CSF1 | PD-0360324 | Avelumab (anti-PDL1 mAb) | 1 | Pfizer | Solid tumors | NCT02554812 | Ongoing | - |
CRC colorectal cancer, CSF1 colony-stimulating factor 1, CSF1R colony-stimulating factor 1 receptor, CTLA4 cytotoxic T-lymphocyte-associated protein 4, GBM glioblastoma, GIST gastrointestinal stromal tumor, mAb monoclonal antibody, MSS microsatellite stable, NSCLC non-small cell lung cancer, PD1 programmed cell death protein 1, PDL1 programmed cell death ligand 1, RCC renal cell carcinoma, SCCHN squamous cell carcinoma of the head and neck, TNBC triple-negative breast cancer, UBC urothelial bladder carcinoma